RELUGOLIX (TAK-385) - Emerging Insight and Market Forecast – 2030

RELUGOLIX (TAK-385) - Emerging Insight and Market Forecast – 2030

  • October 2020 •
  • 50 pages •
  • Report ID: 5982069 •
  • Format: PDF
“RELUGOLIX (TAK-385) - Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Endometriosis in 7 Major Markets. A detailed picture of the RELUGOLIX (TAK-385) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces ovarian estradiol, a hormone known to stimulate the growth of uterine fibroids and endometriosis, and testicular testosterone, a hormone known to stimulate the growth of prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around RELUGOLIX (TAK-385).
• The report contains forecasted sales for RELUGOLIX (TAK-385) till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase II) for Endometriosis.
• The report also features the SWOT analysis with analyst insights and key findings of RELUGOLIX (TAK-385).

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by our team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RELUGOLIX (TAK-385) Analytical Perspective
• In-depth RELUGOLIX (TAK-385) Market Assessment
This report provides a detailed market assessment of RELUGOLIX (TAK-385) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

• RELUGOLIX (TAK-385) Clinical Assessment
The report provides the clinical trials information of RELUGOLIX (TAK-385) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Endometriosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence RELUGOLIX (TAK-385) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Endometriosis are giving market competition to RELUGOLIX (TAK-385) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of RELUGOLIX (TAK-385).
• Our in-depth analysis of the forecasted sales data of RELUGOLIX (TAK-385) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RELUGOLIX (TAK-385).

Key Questions
• Which company is developing RELUGOLIX (TAK-385) along with the phase of the clinical study?
• What is the technology utilized in the development of RELUGOLIX (TAK-385)?
• What is the product type, route of administration and mechanism of action of RELUGOLIX (TAK-385)?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RELUGOLIX (TAK-385) development?
• What are the key designations that have been granted to RELUGOLIX (TAK-385)?
• What is the forecasted market scenario of RELUGOLIX (TAK-385)?
• What is the history of RELUGOLIX (TAK-385) and what is its future?
• What is the forecasted sales of RELUGOLIX (TAK-385) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to RELUGOLIX (TAK-385)?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?